Latest news with #GraemeBryson
Glasgow Times
a day ago
- Health
- Glasgow Times
Three new cancer drugs approved for use for NHS Scotland
The Scottish Medicines Consortium (SMC) approved the drug brentuximab vedotin, also known as Adcetris, which can be used together with chemotherapy as a first-line treatment for adult patients with advanced Hodgkin lymphoma – an uncommon cancer that develops in the lymphatic system. (Image: Image from PA) SMC vice chair Graeme Bryson said the treatment could 'help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse'. Meanwhile, zanubrutinib, also known as Brukinsa, was accepted to treat adults with mantle cell lymphoma – a rare type of the blood cancer non-Hodgkin lymphoma. The SMC has also approved the drug ripretinib – also known as Qinlock – to treat adults with advanced gastrointestinal stromal tumours, which are a rare type of cancer of the digestive system. In addition to these drugs it has agreed the NHS can use mirikizumab, also known as Omvoh, for adults with Crohn's disease, a lifelong condition which is a chronic inflammatory bowel disease. READ NEXT: Rock band to play huge headline show in Glasgow Graeme Bryson said: 'The committee is pleased to be able to accept these new medicines for use by NHS Scotland. 'Brentuximab vedotin, used together with chemotherapy, could help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse. 'Ripretinib provides a fourth-line treatment for advanced gastro-intestinal stromal tumours where currently there is no standard treatment available. 'Zanubrutinib offers an additional oral targeted treatment option for patients with mantle cell lymphoma who have already received one or more lines of treatment. 'Mirikizumab offers an additional treatment option for people with moderate to severe Crohn's disease whose disease is not controlled on standard or biologic treatment.' READ NEXT: Two teens nicked after 'DPD van chased' through streets by cops However, the Scottish Medicines Consortium (SMC) said it could not approve a new treatment for patients with the lung condition chronic obstructive pulmonary disease (COPD) because of a lack of evidence around its cost-effectiveness. It also rejected the drug dupilumab, also known as Dupixent, as a treatment on the NHS for adults with COPD that is controlled on current standard treatments. Bryson said: 'The committee was unable to accept dupilumab for treating patients with COPD as the company's evidence around the cost-effectiveness of the treatment was not sufficient. We would welcome a resubmission from the company.' Joseph Carter, head of the charity Asthma + Lung UK Scotland, added: 'If the cost effectiveness of dupilumab for use by NHS Scotland can be improved, we are hopeful that the Scottish Medicines Consortium will revisit its decision. 'With an estimated 241,000 people living with COPD in Scotland, there is hope that this drug could help guide research for other targeted therapies. 'More lung research is desperately needed to enable a breakthrough to help better control or even cure COPD.'
The National
a day ago
- Health
- The National
Three new cancer drugs approved for use by NHS Scotland
The Scottish Medicines Consortium (SMC) however said it could not approve a new treatment for patients with the lung condition chronic obstructive pulmonary disease (COPD) because of a lack of evidence around its cost-effectiveness. However, the SMC did approve the drug brentuximab vedotin, also known as Adcetris, to be used together with chemotherapy as a first-line treatment for adult patients with advanced Hodgkin lymphoma – an uncommon cancer that develops in the lymphatic system. SMC vice chair Graeme Bryson said the treatment could 'help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse'. READ MORE: Jewish staff at Scottish universities call for full divestment from Israel Meanwhile, zanubrutinib, also known as Brukinsa, was accepted to treat adults with mantle cell lymphoma – a rare type of the blood cancer non-Hodgkin lymphoma. The SMC has also approved the drug ripretinib – also known as Qinlock – to treat adults with advanced gastrointestinal stromal tumours, which are a rare type of cancer of the digestive system. In addition to these drugs it has agreed the NHS can use mirikizumab, also known as Omvoh, for adults with Crohn's disease, a lifelong condition which is a chronic inflammatory bowel disease. However, the SMC rejected the drug dupilumab, also known as Dupixent, as a treatment on the NHS for adults with COPD that is controlled on current standard treatments. Bryson said: 'The committee is pleased to be able to accept these new medicines for use by NHS Scotland. 'Brentuximab vedotin, used together with chemotherapy, could help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse. 'Ripretinib provides a fourth-line treatment for advanced gastro-intestinal stromal tumours where currently there is no standard treatment available. 'Zanubrutinib offers an additional oral targeted treatment option for patients with mantle cell lymphoma who have already received one or more lines of treatment. 'Mirikizumab offers an additional treatment option for people with moderate to severe Crohn's disease whose disease is not controlled on standard or biologic treatment.' However he added: 'The committee was unable to accept dupilumab for treating patients with COPD as the company's evidence around the cost-effectiveness of the treatment was not sufficient. We would welcome a resubmission from the company.' Joseph Carter, head of the charity Asthma + Lung UK Scotland, said: 'If the cost effectiveness of dupilumab for use by NHS Scotland can be improved, we are hopeful that the Scottish Medicines Consortium will revisit its decision. 'With an estimated 241,000 people living with COPD in Scotland, there is hope that this drug could help guide research for other targeted therapies. 'More lung research is desperately needed to enable a breakthrough to help better control or even cure COPD.'
STV News
a day ago
- Health
- STV News
Three new cancer drugs approved for use for NHS Scotland
Three new treatments for cancer have been approved for use by the NHS in Scotland. The Scottish Medicines Consortium (SMC) however said it could not approve a new treatment for patients with the lung condition chronic obstructive pulmonary disease (COPD) because of a lack of evidence around its cost-effectiveness. However, the SMC did approve the drug brentuximab vedotin, also known as Adcetris, to be used together with chemotherapy as a first-line treatment for adult patients with advanced Hodgkin lymphoma – an uncommon cancer that develops in the lymphatic system. SMC vice chair Graeme Bryson said the treatment could 'help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse'. Meanwhile, zanubrutinib, also known as Brukinsa, was accepted to treat adults with mantle cell lymphoma – a rare type of the blood cancer non-Hodgkin lymphoma. The SMC has also approved the drug ripretinib – also known as Qinlock – to treat adults with advanced gastrointestinal stromal tumours, which are a rare type of cancer of the digestive system. In addition to these drugs it has agreed the NHS can use mirikizumab, also known as Omvoh, for adults with Crohn's disease, a lifelong condition which is a chronic inflammatory bowel disease. However, the SMC rejected the drug dupilumab, also known as Dupixent, as a treatment on the NHS for adults with COPD that is controlled on current standard treatments. Mr Bryson said: 'The committee is pleased to be able to accept these new medicines for use by NHS Scotland. 'Brentuximab vedotin, used together with chemotherapy, could help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse. 'Ripretinib provides a fourth-line treatment for advanced gastro-intestinal stromal tumours where currently there is no standard treatment available. 'Zanubrutinib offers an additional oral targeted treatment option for patients with mantle cell lymphoma who have already received one or more lines of treatment. 'Mirikizumab offers an additional treatment option for people with moderate to severe Crohn's disease whose disease is not controlled on standard or biologic treatment.' However he added: 'The committee was unable to accept dupilumab for treating patients with COPD as the company's evidence around the cost-effectiveness of the treatment was not sufficient. We would welcome a resubmission from the company.' Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
Daily Record
a day ago
- Health
- Daily Record
Three new cancer drugs approved for use for NHS Scotland
The drugs have been approved for use by the NHS in Scotland. Three new treatments for cancer have been approved for use by the NHS in Scotland. The Scottish Medicines Consortium (SMC) however said it could not approve a new treatment for patients with the lung condition chronic obstructive pulmonary disease (COPD) because of a lack of evidence around its cost-effectiveness. However, the SMC did approve the drug brentuximab vedotin, also known as Adcetris, to be used together with chemotherapy as a first-line treatment for adult patients with advanced Hodgkin lymphoma – an uncommon cancer that develops in the lymphatic system. SMC vice chair Graeme Bryson said the treatment could 'help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse'. Ex-gangster Ian 'Blink' MacDonald turns back on underworld after pals all die from drugs and shootings Dad of schoolgirl slain in Dunblane massacre warns gun licensing reform does not go far enough Meanwhile, zanubrutinib, also known as Brukinsa, was accepted to treat adults with mantle cell lymphoma – a rare type of the blood cancer non-Hodgkin lymphoma. The SMC has also approved the drug ripretinib – also known as Qinlock – to treat adults with advanced gastrointestinal stromal tumours, which are a rare type of cancer of the digestive system. In addition to these drugs it has agreed the NHS can use mirikizumab, also known as Omvoh, for adults with Crohn's disease, a lifelong condition which is a chronic inflammatory bowel disease. However, the SMC rejected the drug dupilumab, also known as Dupixent, as a treatment on the NHS for adults with COPD that is controlled on current standard treatments. Join the Daily Record WhatsApp community! Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile, select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'. If you're curious, you can read our Privacy Notice. NHS Scotland. ' Brentuximab vedotin, used together with chemotherapy, could help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse. 'Ripretinib provides a fourth-line treatment for advanced gastro-intestinal stromal tumours where currently there is no standard treatment available. 'Zanubrutinib offers an additional oral targeted treatment option for patients with mantle cell lymphoma who have already received one or more lines of treatment. 'Mirikizumab offers an additional treatment option for people with moderate to severe Crohn's disease whose disease is not controlled on standard or biologic treatment.' However he added: 'The committee was unable to accept dupilumab for treating patients with COPD as the company's evidence around the cost-effectiveness of the treatment was not sufficient. We would welcome a resubmission from the company.'
The Herald Scotland
a day ago
- Health
- The Herald Scotland
Three new cancer drugs approved for use for NHS Scotland
However, the SMC did approve the drug brentuximab vedotin, also known as Adcetris, to be used together with chemotherapy as a first-line treatment for adult patients with advanced Hodgkin lymphoma – an uncommon cancer that develops in the lymphatic system. SMC vice chair Graeme Bryson said the treatment could 'help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse'. Meanwhile, zanubrutinib, also known as Brukinsa, was accepted to treat adults with mantle cell lymphoma – a rare type of the blood cancer non-Hodgkin lymphoma. READ MORE: The SMC has also approved the drug ripretinib – also known as Qinlock – to treat adults with advanced gastrointestinal stromal tumours, which are a rare type of cancer of the digestive system. In addition to these drugs it has agreed the NHS can use mirikizumab, also known as Omvoh, for adults with Crohn's disease, a lifelong condition which is a chronic inflammatory bowel disease. However, the SMC rejected the drug dupilumab, also known as Dupixent, as a treatment on the NHS for adults with COPD that is controlled on current standard treatments. Mr Bryson said: 'The committee is pleased to be able to accept these new medicines for use by NHS Scotland. 'Brentuximab vedotin, used together with chemotherapy, could help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse. 'Ripretinib provides a fourth-line treatment for advanced gastro-intestinal stromal tumours where currently there is no standard treatment available. 'Zanubrutinib offers an additional oral targeted treatment option for patients with mantle cell lymphoma who have already received one or more lines of treatment. 'Mirikizumab offers an additional treatment option for people with moderate to severe Crohn's disease whose disease is not controlled on standard or biologic treatment.' However he added: 'The committee was unable to accept dupilumab for treating patients with COPD as the company's evidence around the cost-effectiveness of the treatment was not sufficient. We would welcome a resubmission from the company.'
